Two Sigma Investments LP Buys 42,160 Shares of Aquestive Therapeutics, Inc. (NASDAQ:AQST)

Two Sigma Investments LP increased its stake in Aquestive Therapeutics, Inc. (NASDAQ:AQST) by 31.5% in the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 175,952 shares of the company’s stock after buying an additional 42,160 shares during the period. Two Sigma Investments LP owned 0.19% of Aquestive Therapeutics worth $626,000 at the end of the most recent reporting period.

Other institutional investors also recently bought and sold shares of the company. Vanguard Group Inc. grew its holdings in Aquestive Therapeutics by 1.9% in the fourth quarter. Vanguard Group Inc. now owns 4,346,754 shares of the company’s stock worth $15,474,000 after purchasing an additional 82,958 shares during the period. Bank of America Corp DE grew its holdings in Aquestive Therapeutics by 905.2% in the fourth quarter. Bank of America Corp DE now owns 690,284 shares of the company’s stock worth $2,457,000 after purchasing an additional 621,614 shares during the period. Northern Trust Corp grew its holdings in Aquestive Therapeutics by 3.1% in the fourth quarter. Northern Trust Corp now owns 599,812 shares of the company’s stock worth $2,135,000 after purchasing an additional 18,199 shares during the period. Bracebridge Capital LLC grew its holdings in Aquestive Therapeutics by 7.2% in the fourth quarter. Bracebridge Capital LLC now owns 459,216 shares of the company’s stock worth $1,635,000 after purchasing an additional 30,645 shares during the period. Finally, Stifel Financial Corp grew its holdings in Aquestive Therapeutics by 315.4% in the fourth quarter. Stifel Financial Corp now owns 398,561 shares of the company’s stock worth $1,419,000 after purchasing an additional 302,617 shares during the period. 32.45% of the stock is owned by institutional investors.

Analyst Ratings Changes

A number of equities research analysts have weighed in on AQST shares. Raymond James set a $7.00 price objective on shares of Aquestive Therapeutics in a report on Friday, March 7th. HC Wainwright reiterated a “buy” rating and set a $10.00 price target on shares of Aquestive Therapeutics in a report on Thursday, May 15th. Alliance Global Partners reissued a “buy” rating on shares of Aquestive Therapeutics in a research report on Friday, March 7th. Oppenheimer initiated coverage on shares of Aquestive Therapeutics in a research report on Monday, June 2nd. They set an “outperform” rating and a $7.00 price target for the company. Finally, Lake Street Capital reduced their price target on shares of Aquestive Therapeutics from $10.00 to $8.00 and set a “buy” rating for the company in a research report on Friday, March 7th. Seven research analysts have rated the stock with a buy rating, Based on data from MarketBeat, the company currently has a consensus rating of “Buy” and an average price target of $10.14.

Aquestive Therapeutics Stock Down 0.3%

Shares of AQST opened at $3.56 on Monday. The company has a market capitalization of $353.61 million, a P/E ratio of -7.91 and a beta of 1.94. The firm has a 50 day moving average of $2.69 and a 200 day moving average of $3.12. Aquestive Therapeutics, Inc. has a twelve month low of $2.12 and a twelve month high of $5.80.

Aquestive Therapeutics (NASDAQ:AQST) last issued its earnings results on Monday, May 12th. The company reported ($0.24) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.17) by ($0.07). The company had revenue of $8.72 million for the quarter, compared to the consensus estimate of $12.23 million. On average, sell-side analysts expect that Aquestive Therapeutics, Inc. will post -0.46 EPS for the current year.

Aquestive Therapeutics Company Profile

Aquestive Therapeutics, Inc operates as a pharmaceutical company in the United States and internationally. The company markets Sympazan, an oral soluble film formulation of clobazam for the treatment of lennox-gastaut syndrome; Suboxone, a sublingual film formulation of buprenorphine and naloxone for the treatment of opioid dependence; Zuplenz, an oral soluble film formulation of ondansetron for the treatment of nausea and vomiting associated with chemotherapy and post-operative recovery; and Azstarys, a once-daily product for the treatment of attention deficit hyperactivity disorder.